Merck KGaA brain tumor drug fails clinical trial There was a lot of hope for this drug. Failing the clinical trial does not mean that it is useless. It means that it didn't work in the manner that they used it, which is in combination with the standard treatments. This drug has many effects on the tumor cells: it inhibits cell migration, differentiation, angiogenesis, wound healing, immune and non-immune defense mechanisms, and oncogenic transformation.
It's place may be in combination with other targeted agents and/or vaccines in a well thought out cocktail approach. I hope research on this continues.
